Oncologists should consider neoadjuvant immunotherapy for patients with clinical stage III melanoma, which is a paradigm shift away from upfront surgery and adjuvant systemic therapy, according to a ...
Please provide your email address to receive an email when new articles are posted on . Survival rates increased for all stages of NSCLC from 2016-2020 compared with 2010-2015. Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results